Nicolas Signolle
Overview
Explore the profile of Nicolas Signolle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gessain G, Anzali A, Lerousseau M, Mulder K, Bied M, Auperin A, et al.
Cancer Discov
. 2024 Sep;
14(12):2352-2366.
PMID: 39270324
Novel individual biomarkers are needed to guide therapeutic decisions for patients with head and neck cancer. We report for the first time, granulomas of TREM2-expressing multinucleated giant macrophages in keratin-rich...
2.
Henon C, Vibert J, Eychenne T, Gruel N, Colmet-Daage L, Ngo C, et al.
Cell Rep Med
. 2024 May;
5(6):101582.
PMID: 38781959
Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive sarcoma driven by the EWSR1::WT1 chimeric transcription factor. Despite this unique oncogenic driver, DSRCT displays a polyphenotypic differentiation of unknown...
3.
Gonnelli A, Gerbe de Thore M, Ermini M, Frusca V, Zamborlin A, Signolle N, et al.
Adv Mater
. 2024 May;
36(28):e2400949.
PMID: 38761135
Cisplatin chemoradiotherapy (CRT) is the established standard of care for managing locally advanced human papillomavirus-positive head/neck carcinoma. The typically young patients may suffer serious and long-time side effects caused by...
4.
Laurent P, Milic M, Quevrin C, Meziani L, Liu W, Morel D, et al.
J Transl Med
. 2023 Nov;
21(1):773.
PMID: 37907934
Background: KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS...
5.
Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al.
Nat Med
. 2023 Jul;
29(8):2110-2120.
PMID: 37488289
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2-drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd...
6.
Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, et al.
Leukemia
. 2023 Apr;
37(6):1287-1297.
PMID: 37100881
Heterozygous mutation targeting proline 95 in Serine/Arginine-rich Splicing Factor 2 (SRSF2) is associated with V617F mutation in Janus Activated Kinase 2 (JAK2) in some myeloproliferative neoplasms (MPNs), most commonly primary...
7.
Goubet A, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou M, et al.
Cancer Discov
. 2022 Aug;
12(10):2280-2307.
PMID: 35929803
Significance: In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such...
8.
Baldini C, Danlos F, Varga A, Texier M, Halse H, Mouraud S, et al.
J Exp Clin Cancer Res
. 2022 Jul;
41(1):217.
PMID: 35794623
Background: We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors...
9.
Canet-Jourdan C, Pages D, Nguyen-Vigouroux C, Cartry J, Zajac O, Desterke C, et al.
J Cell Sci
. 2022 Jun;
135(14).
PMID: 35703098
The metastatic progression of cancer remains a major issue in patient treatment. However, the molecular and cellular mechanisms underlying this process remain unclear. Here, we use primary explants and organoids...
10.
Rouanne M, Adam J, Radulescu C, Letourneur D, Bredel D, Mouraud S, et al.
J Clin Invest
. 2022 May;
132(12).
PMID: 35503263
Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain...